05/15/2026
When people leave prison, they enter one of the highest-risk periods for acquiring HIV, often with the fewest resources and the greatest uncertainty about where to turn for care.
Dr. Lina Rosengren is working to close that gap through the RELEASE study, a first-of-its-kind effort to provide long-acting HIV prevention medication to individuals before they transition back into their communities. In partnership with Gilead Sciences, a biopharmaceutical company focused on advancing HIV treatment and prevention, the study combines research, clinical care, and North Carolina’s prison health network to reimagine what continuity of care can look like during one of the most vulnerable moments in a person’s life.
“Gilead has committed to helping us understand and support these individuals with access to one of the most exciting new long-acting medications for PrEP,” says Dr. Rosengren.
Chapel Hill, NC – When people leave prison, they enter one of the highest-risk periods for acquiring HIV—often with the least support, the fewest resources, and the greatest uncertainty about where to turn for care. It’s this critical gap that Lina Rosengren, MD, MPH, an infectious diseases ph...